US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

SMITH-MIDLAND CORP

30.61

-0.0500-0.16%

Post-market: 30.610.00000.00%16:00 EDT

Volume:7.00K

Turnover:217.74K

Market Cap:162.34M

PE:25.10

High:31.44

Open:30.74

Low:30.61

Close:30.66

Loading ...

Overview Company News Filings

EyePoint to Present at Guggenheim SMID Cap Biotech Conference

Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference

Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference

Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference

Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference

Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference

Cabaletta Bio to Participate in Guggenheim’s SMID Cap Biotech Conference

NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference

CRISPR Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference

Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference

Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference

ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference

Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference

Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference

Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference

Tourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotech Conference

InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference

Smith-Midland Corporation (NASDAQ:SMID) is largely controlled by institutional shareholders who own 60% of the company

Simply Wall St.

Easi-Set Worldwide Signs Building License Agreement with Infrastructure Precast, Inc.

ACCESS Newswire

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SMID/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SMID","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SMID\",,,,,undefined,":{"symbol":"SMID","market":"US","secType":"STK","nameCN":"SMITH-MIDLAND CORP","latestPrice":30.61,"timestamp":1746734400000,"preClose":30.66,"halted":0,"volume":6996,"hourTrading":{"tag":"盘后","latestPrice":30.61,"preClose":30.61,"latestTime":"16:00 EDT","volume":168,"amount":5142.81,"timestamp":1746734444881},"delay":0,"floatShares":4546993,"shares":5303606,"eps":1.219701,"marketStatus":"Not Yet Opened","change":-0.05,"latestTime":"05-08 16:00:00 EDT","open":30.74,"high":31.4444,"low":30.61,"amount":217738.4355,"amplitude":0.027215,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.219701,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1746777600000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":30.66,"preHourTrading":{"tag":"盘前","latestPrice":30.28,"preClose":30.66,"latestTime":"04:44 EDT","volume":7,"amount":209.81999499999998,"timestamp":1746693860108},"postHourTrading":{"tag":"盘后","latestPrice":30.61,"preClose":30.61,"latestTime":"16:00 EDT","volume":168,"amount":5142.81,"timestamp":1746734444881},"volumeRatio":1.055395},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SMID\",,,,,undefined,":{"symbol":"SMID","floatShares":4546993,"roa":"8.62%","roe":"17.55%","lyrEps":0.151198,"volumeRatio":1.055395,"shares":5303606,"dividePrice":0,"high":31.4444,"amplitude":0.027215,"preClose":30.66,"low":30.61,"week52Low":25.0301,"pbRate":"4.02","psRate":"2.13","week52High":51.96,"institutionHeld":0.6309,"latestPrice":30.61,"eps":1.219701,"divideRate":0,"volume":6996,"delay":0,"ttmEps":1.219701,"open":30.74,"prevYearClose":44.46,"prevWeekClose":32.16,"prevMonthClose":29.99,"prevQuarterClose":31.07,"fiveDayClose":29.42,"twentyDayClose":31.36,"sixtyDayClose":36.15},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SMID\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2507642861","title":"EyePoint to Present at Guggenheim SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507642861","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507642861?lang=en_us&edition=fundamental","pubTime":"2025-01-30 20:00","pubTimestamp":1738238400,"startTime":"0","endTime":"0","summary":"WATERTOWN, Mass., Jan. 30, 2025  -- EyePoint Pharmaceuticals, Inc. , a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Thursday, February 6, 2025 at 9:30 a.m. ET.Pipeline programs include EYP-2301, a TIE-2 agonist, razuprotafib, formulated in Durasert Eto potentially improve outcomes in serious retinal diseases. The proven Durasertdrug delivery technology has been safely administered to thousands of patient eyes across fourU.S.FDA approved products.EyePoint Pharmaceuticalsis headquartered inWatertown, Massachusetts.DURAVYU has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential ap","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/eyepoint-present-guggenheim-smid-cap-120000292.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2458330243.SGD","LU0109392836.USD","LU1803068979.SGD","LU2054465674.USD","BK4529","LU0889565916.HKD","LU1951198990.SGD","LU0889565833.HKD","LU1880398471.USD","LU0109394709.USD","IE0009356076.USD","LU1242518857.USD","BK4512","IE0004445239.USD","EYPT","LU1242518931.SGD","LU0081259029.USD","LU1303367103.USD","LU0642271901.SGD","LU0198837287.USD","LU0320765992.SGD","BK4588","LU0719512351.SGD","LU1923623000.USD","BK4007","LU2250418816.HKD","BK4575","LU1064131342.USD","LU0823421416.USD","IE00B5949003.HKD","LU2098885051.SGD","LU0390134368.USD","BK4141","LU1951200564.SGD","BK4532","LU0823434740.USD","BK4011","LU1316542783.SGD","SMID","LU0082616367.USD","IE00BMPRXN33.USD","LU0979878070.USD","BK4534","BK4566","LU2264538146.SGD","LU0056508442.USD","BK4573","LU1852331112.SGD","LU1988902786.USD"],"gpt_icon":1},{"id":"2507642708","title":"Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507642708","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507642708?lang=en_us&edition=fundamental","pubTime":"2025-01-30 20:00","pubTimestamp":1738238400,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Jan.  30, 2025  (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that J","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/30/3017859/0/en/Beam-Therapeutics-to-Participate-in-Guggenheim-SMID-Cap-Biotech-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4011","LENZ","SMID"],"gpt_icon":0},{"id":"2507642058","title":"Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507642058","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507642058?lang=en_us&edition=fundamental","pubTime":"2025-01-30 20:00","pubTimestamp":1738238400,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Jan. 30, 2025  -- Cullinan Therapeutics, Inc., a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference, being held in New York on February 5 and 6, 2025.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cullinan-therapeutics-participate-fireside-chat-120000714.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CGEM","BK4011","BK4139","SMID"],"gpt_icon":0},{"id":"2507517642","title":"Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507517642","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507517642?lang=en_us&edition=fundamental","pubTime":"2025-01-30 20:00","pubTimestamp":1738238400,"startTime":"0","endTime":"0","summary":"WATERTOWN, Mass., Jan. 30, 2025  -- Vigil Neuroscience, Inc. , a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on February 6, 2025, at 10:30 a.m. ET.To register for the live webcast, please click here. The webcast will also be available on the Company’s website in the “Investors” section under “Events & Presentations.” An archived webcast will be available for approximately 90 days following the event.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vigil-neuroscience-present-guggenheim-securities-120000141.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VIGL","BK4011","BK4139","SMID"],"gpt_icon":0},{"id":"2507420556","title":"Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507420556","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507420556?lang=en_us&edition=fundamental","pubTime":"2025-01-30 20:00","pubTimestamp":1738238400,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Jan.  30, 2025  (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc.(Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, tod","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/30/3017883/0/en/Cullinan-Therapeutics-to-Participate-in-Fireside-Chat-at-the-Guggenheim-Securities-SMID-Cap-Biotech-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4011","CGEM","BK4139","SMID"],"gpt_icon":0},{"id":"2507663054","title":"Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507663054","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507663054?lang=en_us&edition=fundamental","pubTime":"2025-01-30 05:05","pubTimestamp":1738184700,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., Jan.  29, 2025  (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for patients with RAS-addicte","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/29/3017572/0/en/Revolution-Medicines-to-Participate-in-the-Guggenheim-Securities-SMID-Cap-Biotech-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU1854103824.USD","LU2357305700.SGD","LU0124384867.USD","RVMD","MDCO","BK4141","LU1861214812.USD","LU1720051108.HKD","LU0348723411.USD","LU0724618433.USD","LU1720051017.SGD","LU1548497426.USD","LU1861215975.USD","LU1861219969.SGD","BK4512","BK4011","BK4588","LU1861220033.SGD","LU1978683503.SGD","LU2360107325.USD","IE00BD6J9T35.USD","IE00BZ199S13.USD","BK4139","ON","LU1854104046.USD","SMID","LU2298322129.HKD"],"gpt_icon":0},{"id":"2507663809","title":"Cabaletta Bio to Participate in Guggenheim’s SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507663809","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507663809?lang=en_us&edition=fundamental","pubTime":"2025-01-29 21:00","pubTimestamp":1738155600,"startTime":"0","endTime":"0","summary":"PHILADELPHIA, Jan.  29, 2025  (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therap","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/29/3017090/0/en/Cabaletta-Bio-to-Participate-in-Guggenheim-s-SMID-Cap-Biotech-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CABA","BK4011","BK4139","SMID"],"gpt_icon":0},{"id":"2507638909","title":"NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507638909","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507638909?lang=en_us&edition=fundamental","pubTime":"2025-01-29 21:00","pubTimestamp":1738155600,"startTime":"0","endTime":"0","summary":"NAARDEN, The Netherlands and MIAMI, Jan. 29, 2025  -- NewAmsterdam Pharma Company N.V. , a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease  with elevated low-density lipoprotein cholesterol , for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Ian Somaiya, Chief Financial Officer of NewAmsterdam Pharma, will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Wednesday, February 5, 2025 at 10:00 a.m. ET.NewAmsterdam Pharma  is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/newamsterdam-pharma-present-guggenheim-smid-130000812.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NAMS","SMID","BK4011","NAMSW"],"gpt_icon":0},{"id":"2507638004","title":"CRISPR Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507638004","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507638004?lang=en_us&edition=fundamental","pubTime":"2025-01-29 21:00","pubTimestamp":1738155600,"startTime":"0","endTime":"0","summary":"ZUG, Switzerland and BOSTON, Jan.  29, 2025  (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious dis","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/29/3017123/0/en/CRISPR-Therapeutics-to-Present-at-the-Guggenheim-SMID-Cap-Biotech-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","CRSP","LENZ","BK4556","BK4011","LU1861559042.SGD","LU1861558580.USD","SMID","BK4588","BK4139"],"gpt_icon":0},{"id":"2507463849","title":"Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507463849","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507463849?lang=en_us&edition=fundamental","pubTime":"2025-01-29 21:00","pubTimestamp":1738155600,"startTime":"0","endTime":"0","summary":"FLORHAM PARK, N.J., Jan. 29, 2025  -- Phathom Pharmaceuticals, Inc. , a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal  diseases, announced today that members of the management team will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on Thursday, February 6, 2025, at 10:00 am ET.Company management will also participate in one-on-one meetings during the conference, which will run from February 5-6, 2025, in New York, NY.2025 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/phathom-pharmaceuticals-present-guggenheim-securities-130000473.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SMID","PHAT","BK4007","BK4011"],"gpt_icon":0},{"id":"2507868047","title":"Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507868047","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507868047?lang=en_us&edition=fundamental","pubTime":"2025-01-29 20:30","pubTimestamp":1738153800,"startTime":"0","endTime":"0","summary":"BOSTON, January 29, 2025----Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Wednesday, Feb. 5, 2025, at 1:00 pm EST.A live webcast of the fireside chat can be accessed under \"Events & Presentations\" in the Investors & Media section of the company’s website at www.verastem.com. A replay of the webcast will be archived on the website for approximately 90 days following the presentation.Verastem Oncology  is a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/verastem-oncology-present-guggenheim-smid-123000272.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SMID","VSTM","BK4139","BK4011"],"gpt_icon":0},{"id":"2507768066","title":"ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507768066","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507768066?lang=en_us&edition=fundamental","pubTime":"2025-01-29 20:30","pubTimestamp":1738153800,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Massachusetts, Jan.  29, 2025  (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/29/3017073/0/en/ProMIS-Neurosciences-to-Participate-in-Guggenheim-Securities-SMID-Cap-Biotech-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4011","LU2211815571.USD","LU0757428866.USD","BK4143","LU2125909759.SGD","MSA","LU1815336091.USD","LU1923622291.USD","LU0728928796.USD","LU0053671581.USD","LU2125909916.SGD","SMID"],"gpt_icon":0},{"id":"2507662680","title":"Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507662680","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507662680?lang=en_us&edition=fundamental","pubTime":"2025-01-29 20:30","pubTimestamp":1738153800,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO and BOSTON, Jan.  29, 2025  (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Guggenhei","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/29/3017070/0/en/Apogee-Therapeutics-to-Participate-at-the-Guggenheim-SMID-Cap-Biotech-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SMID","BK4011","APGE"],"gpt_icon":0},{"id":"2507687851","title":"Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507687851","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507687851?lang=en_us&edition=fundamental","pubTime":"2025-01-29 20:00","pubTimestamp":1738152000,"startTime":"0","endTime":"0","summary":"BOSTON, Jan. 29, 2025  -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on Wednesday, February 5, 2025 at 9 a.m. ET in New York.A live webcast will be available in the investor section of the company’s website at www.vervetx.com. The webcast will be archived for 90 days following the presentation.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/verve-therapeutics-participate-guggenheim-securities-120000499.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4011","SMID","BK4139","VERV","BK4539"],"gpt_icon":0},{"id":"2507687414","title":"Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507687414","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507687414?lang=en_us&edition=fundamental","pubTime":"2025-01-29 20:00","pubTimestamp":1738152000,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif. & BOSTON, January 29, 2025----Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference being held from February 5-6, 2025 in New York.Details of the event are as follows:Date: Wednesday, February 5, 2025Time: 2:00 p.m. ET","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adicet-bio-participate-fireside-chat-120000750.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4011","ACET","BK4139","SMID"],"gpt_icon":0},{"id":"2506513319","title":"Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2506513319","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506513319?lang=en_us&edition=fundamental","pubTime":"2025-01-28 21:00","pubTimestamp":1738069200,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Jan.  28, 2025  (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/28/3016303/0/en/Zenas-BioPharma-to-Present-at-the-Guggenheim-SMID-Cap-Biotech-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SMID","BK4011","ZBIO"],"gpt_icon":0},{"id":"2506837654","title":"Tourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2506837654","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506837654?lang=en_us&edition=fundamental","pubTime":"2025-01-27 20:00","pubTimestamp":1737979200,"startTime":"0","endTime":"0","summary":"NEW YORK, Jan. 27, 2025  -- Tourmaline Bio, Inc.  , a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced thatSandeep Kulkarni, MD, Co-Founder and Chief Executive Officer, is expected to participate in the following investor conference:. Guggenheim Securities SMID Cap Biotech Conference, New YorkFireside ChatWednesday, February 5, 2025,at1:30 pm ET","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tourmaline-bio-present-guggenheim-securities-120000523.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4011","BK4139","SMID","TRML"],"gpt_icon":0},{"id":"2505772092","title":"InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2505772092","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505772092?lang=en_us&edition=fundamental","pubTime":"2025-01-23 20:30","pubTimestamp":1737635400,"startTime":"0","endTime":"0","summary":"JENA, Germany, Jan.  23, 2025  (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announce","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/23/3014168/0/en/InflaRx-Announces-Participation-in-Guggenheim-SMID-Cap-Biotech-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4011","SMID","USA"],"gpt_icon":0},{"id":"2505092576","title":"Smith-Midland Corporation (NASDAQ:SMID) is largely controlled by institutional shareholders who own 60% of the company","url":"https://stock-news.laohu8.com/highlight/detail?id=2505092576","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505092576?lang=en_us&edition=fundamental","pubTime":"2025-01-23 19:54","pubTimestamp":1737633284,"startTime":"0","endTime":"0","summary":"Significantly high institutional ownership implies Smith-Midland's stock price is sensitive to their trading actions. 53% of the business is held by the top 4 shareholders. A look at the shareholders of Smith-Midland Corporation  can tell us which group is most powerful. The group holding the most number of shares in the company, around 60% to be precise, is institutions. That is, the group stands to benefit the most if the stock rises .Since institutional have access to huge amounts of capital, their market moves tend to receive a lot of scrutiny by retail or individual investors. As a result, a sizeable amount of institutional money invested in a firm is generally viewed as a positive attribute.Let's take a closer look to see what the different types of shareholders can tell us about Smith-Midland.While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. We're not picking up on any ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/smith-midland-corporation-nasdaq-smid-115444370.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PSQ","USAW.SI","IE00BKPKM429.USD","TQQQ","IE00BGHQF748.EUR","QID","LU2210150020.SGD","BK4588","USJW.SI","SQQQ","BK4011","IE00B3QW5Z07.USD","BK4585","NQmain","LU2095319765.USD","NDAQ","NVIW.SI","BK4112","MNQmain","TSYW.SI","QLD",".IXIC","LU2210149790.SGD","SMID","IE00B64PRP62.GBP"],"gpt_icon":1},{"id":"2505273307","title":"Easi-Set Worldwide Signs Building License Agreement with Infrastructure Precast, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2505273307","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505273307?lang=en_us&edition=fundamental","pubTime":"2025-01-21 21:30","pubTimestamp":1737466200,"startTime":"0","endTime":"0","summary":"MIDLAND, VA / ACCESS Newswire / January 21, 2025 / Easi-Set Worldwide, a subsidiary of Smith-Midland Corporation , is excited to announce a new licensing agreement with Infrastructure Precast Inc.  of Kentucky. Under this agreement, ICast will produce Easi-Set and Easi-Span precast concrete modular buildings for Kentucky, Middle Tennessee, and Southern Indiana. ICast is currently licensed to manufacture the Easi-Set J-J Hooks precast concrete barrier.\"We truly consider it a privilege to partner with Easi-Set on various product lines and look forward to growing markets together,\" said Jonathon Ross, PE, President and CEO of Infrastructure Precast, Inc.Forward-Looking StatementsThis announcement contains forward-looking statements, which involve risks and uncertainties. The Company's actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, product demand, the impact of","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/easi-set-worldwide-signs-building-133000944.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SMID","BK4011"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":80,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SMID\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-11-14","symbol":"SMID","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":0.59},{"market":"US","date":"2024-08-14","symbol":"SMID","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"post","actualEps":0.37},{"market":"US","date":"2024-06-11","symbol":"SMID","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1718078400000,"reportTimeType":"post","actualEps":0.21},{"market":"US","date":"2024-05-23","symbol":"SMID","fiscalQuarterEnding":"2023/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1716436800000,"reportTimeType":"post","actualEps":0.04},{"market":"US","date":"2023-11-09","symbol":"SMID","fiscalQuarterEnding":"2023/09","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1699506000000,"reportTimeType":"","actualEps":0.24}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SMID\",market:\"US\",,,undefined,":[{"executeDate":"2015-12-16","recordDate":"2015-12-18","paymentDate":"2015-12-30","value":0.04,"currency":"USD"},{"executeDate":"2016-12-28","recordDate":"2016-12-30","paymentDate":"2017-01-13","value":0.01,"currency":"USD"},{"executeDate":"2018-12-18","recordDate":null,"paymentDate":null,"value":0.055,"currency":"USD"},{"executeDate":"2019-12-19","recordDate":"2019-12-20","paymentDate":null,"value":0.055,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SMID\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SMID\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SMID","date":"2025-05-07","current":25.10819,"percent":0.056962,"low":20.854222,"twenty":30.904018,"median":39.931883,"eighty":348.884472,"high":430.955547,"avg":147.343349,"sd":151.862128,"marketCap":163404100},"quantilePoints":[{"date":"2024-01-05","current":371.443946,"twenty":371.443946,"median":371.443946,"eighty":371.443946,"marketCap":211351605},{"date":"2024-01-12","current":364.577223,"twenty":364.394111,"median":366.316793,"eighty":371.443946,"marketCap":207444440},{"date":"2024-01-19","current":350.01977,"twenty":354.542651,"median":364.485667,"eighty":368.733879,"marketCap":199161249},{"date":"2024-01-26","current":383.98716,"twenty":357.893612,"median":365.950568,"eighty":375.14282,"marketCap":218488694},{"date":"2024-02-02","current":364.668779,"twenty":358.122503,"median":366.774575,"eighty":374.923085,"marketCap":207496535},{"date":"2024-02-09","current":411.911835,"twenty":362.526361,"median":368.056362,"eighty":380.398154,"marketCap":234377834},{"date":"2024-02-16","current":407.334019,"twenty":364.210998,"median":373.961745,"eighty":391.275043,"marketCap":231773057},{"date":"2024-02-23","current":402.481534,"twenty":364.503978,"median":375.838648,"eighty":397.766385,"marketCap":229011993},{"date":"2024-03-01","current":419.602564,"twenty":364.632157,"median":378.676895,"eighty":406.857926,"marketCap":238753859},{"date":"2024-03-08","current":288.310817,"twenty":361.574176,"median":376.708433,"eighty":406.436768,"marketCap":164048855},{"date":"2024-03-15","current":318.707511,"twenty":352.601658,"median":374.831529,"eighty":405.722628,"marketCap":181344574},{"date":"2024-03-22","current":406.143787,"twenty":354.487717,"median":375.838648,"eighty":405.649383,"marketCap":231095815},{"date":"2024-03-28","current":402.481534,"twenty":355.055367,"median":376.708433,"eighty":405.814184,"marketCap":229011993},{"date":"2024-04-05","current":402.847761,"twenty":356.932271,"median":379.500902,"eighty":406.986105,"marketCap":229220376},{"date":"2024-04-12","current":373.458185,"twenty":360.62199,"median":381.423584,"eighty":407.297396,"marketCap":212497707},{"date":"2024-04-19","current":343.610828,"twenty":356.932271,"median":377.852888,"eighty":406.986105,"marketCap":195514561},{"date":"2024-04-26","current":339.033012,"twenty":351.484671,"median":375.838648,"eighty":406.491701,"marketCap":192909784},{"date":"2024-05-03","current":338.8499,"twenty":338.923145,"median":373.458185,"eighty":406.253655,"marketCap":192805593},{"date":"2024-05-10","current":307.629199,"twenty":336.982151,"median":370.253714,"eighty":405.814184,"marketCap":175041014},{"date":"2024-05-17","current":335.096091,"twenty":332.679005,"median":367.781694,"eighty":404.330972,"marketCap":190669676},{"date":"2024-05-24","current":315.77771,"twenty":332.679005,"median":366.774574,"eighty":402.70127,"marketCap":179677517},{"date":"2024-05-31","current":243.243577,"twenty":329.675959,"median":365.675899,"eighty":402.481534,"marketCap":193378644},{"date":"2024-06-07","current":221.387574,"twenty":320.373836,"median":364.577223,"eighty":402.371667,"marketCap":176003121},{"date":"2024-06-14","current":103.82899,"twenty":307.629199,"median":364.394111,"eighty":401.932197,"marketCap":193329580},{"date":"2024-06-21","current":92.953443,"twenty":301.439992,"median":358.717619,"eighty":401.199747,"marketCap":173079310},{"date":"2024-06-28","current":78.505306,"twenty":301.000521,"median":355.742039,"eighty":400.888455,"marketCap":146176879},{"date":"2024-07-05","current":73.651635,"twenty":287.76148,"median":354.322916,"eighty":400.37574,"marketCap":137139344},{"date":"2024-07-12","current":83.612948,"twenty":243.243577,"median":351.255781,"eighty":396.026815,"marketCap":155687309},{"date":"2024-07-15","current":83.076786,"twenty":239.219562,"median":350.01977,"eighty":395.541567,"marketCap":154688976},{"date":"2024-08-02","current":95.239183,"twenty":237.221196,"median":347.181524,"eighty":395.056318,"marketCap":177335358},{"date":"2024-08-09","current":82.709939,"twenty":225.706685,"median":343.33616,"eighty":393.344215,"marketCap":154005907},{"date":"2024-08-16","current":36.655516,"twenty":102.484673,"median":340.269023,"eighty":392.11736,"marketCap":169531762},{"date":"2024-08-23","current":36.093702,"twenty":98.427931,"median":338.758344,"eighty":390.634149,"marketCap":166933371},{"date":"2024-08-30","current":40.221317,"twenty":87.349146,"median":337.018774,"eighty":388.253685,"marketCap":186023592},{"date":"2024-09-06","current":34.14455,"twenty":83.392839,"median":334.729866,"eighty":385.049213,"marketCap":157918545},{"date":"2024-09-13","current":37.435177,"twenty":80.491925,"median":332.349402,"eighty":384.426631,"marketCap":173137693},{"date":"2024-09-20","current":43.764187,"twenty":78.211828,"median":329.785826,"eighty":383.858981,"marketCap":202409364},{"date":"2024-09-27","current":39.584976,"twenty":74.057989,"median":329.053374,"eighty":382.577192,"marketCap":183080516},{"date":"2024-10-04","current":35.715337,"twenty":43.489013,"median":317.242611,"eighty":379.336101,"marketCap":165183434},{"date":"2024-10-11","current":39.670968,"twenty":41.202772,"median":307.629199,"eighty":378.512094,"marketCap":183478229},{"date":"2024-10-18","current":37.607161,"twenty":40.301576,"median":302.822492,"eighty":377.688086,"marketCap":173933119},{"date":"2024-10-25","current":36.804569,"twenty":39.673261,"median":300.945587,"eighty":376.900701,"marketCap":170221131},{"date":"2024-10-31","current":38.742255,"twenty":39.338466,"median":288.310817,"eighty":376.387986,"marketCap":179182929},{"date":"2024-11-08","current":41.562792,"twenty":39.269672,"median":262.6784,"eighty":375.289311,"marketCap":192227913},{"date":"2024-11-15","current":27.789331,"twenty":39.269672,"median":243.243577,"eighty":374.831529,"marketCap":180852964},{"date":"2024-11-22","current":36.655839,"twenty":38.673461,"median":236.428563,"eighty":373.458185,"marketCap":238556197},{"date":"2024-11-29","current":40.013376,"twenty":38.554219,"median":226.952073,"eighty":373.165205,"marketCap":260407054},{"date":"2024-12-06","current":38.799121,"twenty":38.554219,"median":221.387574,"eighty":371.773549,"marketCap":252504681},{"date":"2024-12-13","current":40.518637,"twenty":38.574497,"median":102.708726,"eighty":369.539575,"marketCap":263695290},{"date":"2024-12-20","current":35.669766,"twenty":38.301976,"median":99.671306,"eighty":368.257786,"marketCap":232138834},{"date":"2024-12-27","current":38.090127,"twenty":38.160211,"median":97.750675,"eighty":367.891561,"marketCap":247890544},{"date":"2025-01-03","current":35.8735,"twenty":38.026802,"median":93.122757,"eighty":367.708449,"marketCap":233464736},{"date":"2025-01-10","current":32.41002,"twenty":37.861697,"median":83.612948,"eighty":367.561959,"marketCap":210924410},{"date":"2025-01-17","current":33.363496,"twenty":37.645079,"median":83.401305,"eighty":367.159111,"marketCap":217129629},{"date":"2025-01-24","current":33.550931,"twenty":37.458108,"median":82.893362,"eighty":366.13368,"marketCap":218349459},{"date":"2025-01-31","current":33.070118,"twenty":37.40078,"median":80.480637,"eighty":365.950568,"marketCap":215220331},{"date":"2025-02-07","current":30.584563,"twenty":36.919225,"median":78.67462,"eighty":365.40123,"marketCap":199044333},{"date":"2025-02-14","current":30.454173,"twenty":36.655516,"median":76.445317,"eighty":364.668779,"marketCap":198195756},{"date":"2025-02-21","current":30.242289,"twenty":36.093702,"median":75.683404,"eighty":364.595534,"marketCap":196816818},{"date":"2025-02-28","current":27.715986,"twenty":35.893058,"median":73.313007,"eighty":364.430733,"marketCap":180375640},{"date":"2025-03-07","current":27.618194,"twenty":35.775708,"median":43.420219,"eighty":364.394111,"marketCap":179739207},{"date":"2025-03-14","current":26.526179,"twenty":35.319343,"median":42.738016,"eighty":363.66166,"marketCap":172632375},{"date":"2025-03-21","current":26.884751,"twenty":34.845366,"median":42.227797,"eighty":359.669805,"marketCap":174965961},{"date":"2025-03-28","current":28.661313,"twenty":34.002405,"median":41.774906,"eighty":356.337155,"marketCap":186527823},{"date":"2025-04-04","current":22.402601,"twenty":33.539522,"median":41.195893,"eighty":354.826476,"marketCap":145796128},{"date":"2025-04-11","current":23.902084,"twenty":33.350457,"median":40.914787,"eighty":354.37785,"marketCap":155554763},{"date":"2025-04-17","current":24.334,"twenty":32.876164,"median":40.680642,"eighty":353.93838,"marketCap":158365675},{"date":"2025-04-25","current":24.47254,"twenty":32.35516,"median":40.221317,"eighty":352.967884,"marketCap":159267288},{"date":"2025-05-02","current":23.975428,"twenty":31.735252,"median":40.013376,"eighty":351.008578,"marketCap":156032088},{"date":"2025-05-07","current":25.10819,"twenty":30.904018,"median":39.931883,"eighty":348.884472,"marketCap":163404100}],"updateTime":1746740380366}}}